G1 Therapeutics and Genor Biopharma Announce Exclusive License Agreement for Lerociclib in Asia-Pacific Region - Seite 2
“We see significant unmet medical need in Asian patients with HR+, HER2- breast cancer in both adjuvant and metastatic settings, especially among intermediate and high-risk patients whose longer treatment duration requires therapeutics with better tolerability. Lerociclib is a potentially best-in-class CDK4/6 inhibitor, with robust efficacy and a differentiated safety profile when compared with marketed products,” commented Guo Feng, Ph.D., Chief Executive Officer of Genor. “With lerociclib as a strategic fit in our portfolio, we look forward to working with G1 to maximize the potential of this compound in the APAC region.”
About Lerociclib
Lerociclib is a differentiated oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in certain types of breast and lung
cancer. Preliminary clinical data in estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer have demonstrated proof-of-concept of the differentiated clinical profile of lerociclib
versus currently marketed CDK4/6 inhibitors, with improved tolerability and less neutropenia. Neutropenia is one of the main toxicities associated with CDK4/6 inhibition. Current treatments require
frequent blood testing for neutropenia. Less monitoring would mean fewer office visits and blood draws, improving the experience for patients and reducing the burden on physician offices and costs
to the healthcare system.
About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer.
The company is advancing three clinical-stage programs. Trilaciclib is a first-in-class FDA-designated Breakthrough Therapy designed to improve outcomes for patients being treated with chemotherapy.
Rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. Lerociclib is a differentiated oral CDK4/6 inhibitor designed to enable more effective combination treatment strategies.
G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
Lesen Sie auch
About Genor Biopharma
Genor Biopharma is a pre-commercial stage biopharmaceutical company located in Zhangjiang, Shanghai, China. Genor is focused on the therapeutic areas of oncology and autoimmune diseases. The
Company delivers a portfolio of novel therapies built to address unmet medical needs. The Company’s leading product candidates are late stage innovative monoclonal antibodies. Under the leadership
of a management team with more than 20 years of experience in global biopharmaceutical companies such as Pfizer, Merck, Amgen, and AbbVie, Genor currently has about 400 employees across 3 sites in
China - Shanghai Zhangjiang, Yunnan Yuxi, and Beijing office, as well as a lab in South San Francisco, US, among which more than 80% are R&D specialists.